Vaccination against Clostridium difficile using toxin fragments

References

• Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30:57 - 66; http://dx.doi.org/10.1086/592981; PMID: 19049438
   PubMed Web of Science ®Google Scholar
• Chaves-Olarte E, Weidmann M, Eichel-Streiber C, Thelestam M. Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest 1997; 100:1734 - 41; http://dx.doi.org/10.1172/JCI119698; PMID: 9312171
   PubMed Web of Science ®Google Scholar
• Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257 - 62; http://dx.doi.org/10.1056/NEJM199401273300406; PMID: 8043060
   PubMed Web of Science ®Google Scholar
• Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. A mouse model of Clostridium difficile-associated disease. Gastroenterology 2008; 135:1984 - 92; http://dx.doi.org/10.1053/j.gastro.2008.09.002; PMID: 18848941
   PubMed Web of Science ®Google Scholar
• Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8:e1002995; http://dx.doi.org/10.1371/journal.ppat.1002995; PMID: 23133377
   PubMed Web of Science ®Google Scholar
• Arruda PH, Madson DM, Ramirez A, Rowe E, Lizer JT, Songer JG. Effect of age, dose and antibiotic therapy on the development of Clostridium difficile infection in neonatal piglets. Anaerobe 2013; 22:104 - 10; http://dx.doi.org/10.1016/j.anaerobe.2013.04.010; PMID: 23624068
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr., Leney M, Sloan S, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197 - 205; http://dx.doi.org/10.1056/NEJMoa0907635; PMID: 20089970
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390 - 7; http://dx.doi.org/10.1056/NEJM200002103420604; PMID: 10666429
   PubMed Web of Science ®Google Scholar
• Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28:965 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.10.144; PMID: 19941990
   PubMed Web of Science ®Google Scholar
• Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 2013; 207:323 - 30; http://dx.doi.org/10.1093/infdis/jis669; PMID: 23125448
   PubMed Web of Science ®Google Scholar
• Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012; 80:2678 - 88; http://dx.doi.org/10.1128/IAI.00215-12; PMID: 22615245
   PubMed Web of Science ®Google Scholar
• Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WD Jr.. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999; 67:527 - 38; PMID: 9916055
   PubMed Web of Science ®Google Scholar
• Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995; 63:4619 - 27; PMID: 7591115
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr., Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988 - 95; http://dx.doi.org/10.1128/IAI.69.2.988-995.2001; PMID: 11159994
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012; 30:2245 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.01.065; PMID: 22306375
   PubMed Web of Science ®Google Scholar
• Siddiqui F, O’Connor JR, Nagaro K, Cheknis A, Sambol SP, Vedantam G, Gerding DN, Johnson S. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. J Infect Dis 2012; 205:128 - 33; http://dx.doi.org/10.1093/infdis/jir688; PMID: 22124129
   PubMed Web of Science ®Google Scholar
• Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun 1999; 67:5124 - 32; PMID: 10496886
   PubMed Web of Science ®Google Scholar
• Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012; 30:4249 - 58; http://dx.doi.org/10.1016/j.vaccine.2012.04.045; PMID: 22537987
   PubMed Web of Science ®Google Scholar
• Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, et al. Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun 2013; 81:2851 - 60; http://dx.doi.org/10.1128/IAI.01341-12; PMID: 23716610
   PubMed Web of Science ®Google Scholar
• Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. Carbohydrate recognition by Clostridium difficile toxin A. Nat Struct Mol Biol 2006; 13:460 - 1; http://dx.doi.org/10.1038/nsmb1084; PMID: 16622409
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Johnson JL, Frey SM, Wilkins TD. Vaccination against lethal Clostridium enterocolitis with a nontoxic recombinant peptide of toxin A. Curr Microbiol 1990; 21:29 - 32; http://dx.doi.org/10.1007/BF02090096
   Web of Science ®Google Scholar
• Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 1997; 65:2941 - 9; PMID: 9199470
   PubMed Web of Science ®Google Scholar
• Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009; 27:3598 - 604; http://dx.doi.org/10.1016/j.vaccine.2009.03.058; PMID: 19464540
   PubMed Web of Science ®Google Scholar
• Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 2011; 79:2295 - 302; http://dx.doi.org/10.1128/IAI.00130-11; PMID: 21482682
   PubMed Web of Science ®Google Scholar
• Seregin SS, Aldhamen YA, Rastall DP, Godbehere S, Amalfitano A. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 2012; 30:1492 - 501; http://dx.doi.org/10.1016/j.vaccine.2011.12.064; PMID: 22200503
   PubMed Web of Science ®Google Scholar
• Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38:779 - 86; http://dx.doi.org/10.1038/ng1830; PMID: 16804543
   PubMed Web of Science ®Google Scholar
• Vohra P, Poxton IR. Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile.. Microbiology 2011; 157:1343 - 53; http://dx.doi.org/10.1099/mic.0.046243-0; PMID: 21330434
   PubMed Web of Science ®Google Scholar
• He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile.. Nat Genet 2013; 45:109 - 13; http://dx.doi.org/10.1038/ng.2478; PMID: 23222960
   PubMed Web of Science ®Google Scholar
• Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009; 10:R102; http://dx.doi.org/10.1186/gb-2009-10-9-r102; PMID: 19781061
   PubMed Web of Science ®Google Scholar
• Lanis JM, Heinlen LD, James JA, Ballard JD. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 2013; 9:e1003523; http://dx.doi.org/10.1371/journal.ppat.1003523; PMID: 23935501
   PubMed Web of Science ®Google Scholar
• Hamm EE, Voth DE, Ballard JD. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A 2006; 103:14176 - 81; http://dx.doi.org/10.1073/pnas.0604725103; PMID: 16966605
   PubMed Web of Science ®Google Scholar
• Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, Schenck LP, Vilaysane A, Seamone ME, Feng H, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010; 139:542 - 52, e1-3; http://dx.doi.org/10.1053/j.gastro.2010.04.005; PMID: 20398664
   PubMed Web of Science ®Google Scholar
• Wang J, Ando T, Dunn AJ. Effect of homologous interleukin-1, interleukin-6 and tumor necrosis factor-alpha on the core body temperature of mice. Neuroimmunomodulation 1997; 4:230 - 6; PMID: 9650815
   PubMed Web of Science ®Google Scholar
• Ní Eidhin DB, O’Brien JB, McCabe MS, Athié-Morales V, Kelleher DP. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 2008; 52:207 - 18; http://dx.doi.org/10.1111/j.1574-695X.2007.00363.x; PMID: 18093141
   PubMedGoogle Scholar
• Péchiné S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, Fattal E, Collignon A. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile.. Vaccine 2007; 25:3946 - 54; http://dx.doi.org/10.1016/j.vaccine.2007.02.055; PMID: 17433506
   PubMed Web of Science ®Google Scholar
• Péchiné S, Denève C, Le Monnier A, Hoys S, Janoir C, Collignon A. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol Med Microbiol 2011; 63:73 - 81; http://dx.doi.org/10.1111/j.1574-695X.2011.00832.x; PMID: 21707776
   PubMed Web of Science ®Google Scholar
• Sandolo C, Péchiné S, Le Monnier A, Hoys S, Janoir C, Coviello T, Alhaique F, Collignon A, Fattal E, Tsapis N. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile.. Eur J Pharm Biopharm 2011; 79:566 - 73; http://dx.doi.org/10.1016/j.ejpb.2011.05.011; PMID: 21664462
   PubMed Web of Science ®Google Scholar
• Dawson LF, Valiente E, Faulds-Pain A, Donahue EH, Wren BW. Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS One 2012; 7:e50527; http://dx.doi.org/10.1371/journal.pone.0050527; PMID: 23236376
   PubMed Web of Science ®Google Scholar
• Ðapa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M, Minton NP, Serruto D, Unnikrishnan M. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile.. J Bacteriol 2013; 195:545 - 55; http://dx.doi.org/10.1128/JB.01980-12; PMID: 23175653
   PubMed Web of Science ®Google Scholar
• Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012; 55:Suppl 2 S104 - 9; http://dx.doi.org/10.1093/cid/cis357; PMID: 22752857
   PubMed Web of Science ®Google Scholar
• Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 2012; 50:4078 - 82; http://dx.doi.org/10.1128/JCM.02291-12; PMID: 23052318
   PubMed Web of Science ®Google Scholar
• Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011; 108:Suppl 1 4586 - 91; http://dx.doi.org/10.1073/pnas.1000097107; PMID: 20571116
   PubMed Web of Science ®Google Scholar
• Best EL, Fawley WN, Parnell P, Wilcox MH. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 2010; 50:1450 - 7; http://dx.doi.org/10.1086/652648; PMID: 20415567
   PubMed Web of Science ®Google Scholar
• Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608 - 10; http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003; PMID: 12595488
   PubMed Web of Science ®Google Scholar
• Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764 - 70; http://dx.doi.org/10.1053/j.gastro.2004.11.004; PMID: 15765411
   PubMed Web of Science ®Google Scholar
• Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters. J Med Microbiol 2013; 62:1394 - 404; http://dx.doi.org/10.1099/jmm.0.056796-0; PMID: 23518659
   PubMed Web of Science ®Google Scholar
• Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.. Microbiology 2013; 159:1254 - 66; http://dx.doi.org/10.1099/mic.0.066712-0; PMID: 23629868
   PubMed Web of Science ®Google Scholar